Kidney stone recurrence affects millions of Americans, yet the medications proven to prevent repeat episodes remain financially out of reach for many patients despite generic availability. This pricing barrier forces patients to choose between their kidney health and household budgets, often leading to treatment abandonment and costly emergency interventions. A comprehensive cost analysis reveals that Medicare Part D could achieve dramatic savings by adopting the transparent pricing model used by direct-to-consumer pharmaceutical companies. Researchers compared current Medicare Part D prices against alternative procurement costs for seven essential kidney stone prevention medications, including allopurinol for uric acid stones, thiazide diuretics for calcium stones, and potassium citrate for metabolic acidification. The analysis encompassed multiple dosing regimens and found potential annual savings ranging from $900,000 for indapamide to $26 million for chlorthalidone, with total estimated savings approaching $57 million across all medications studied. These findings expose significant inefficiencies in pharmaceutical pricing within Medicare Part D, where administrative layers and profit margins substantially inflate costs for generic medications that have been available for decades. The research demonstrates how alternative procurement models could preserve Medicare sustainability while improving patient access to evidence-based preventive therapies. However, the analysis focuses solely on drug acquisition costs without examining potential implementation barriers, formulary management complexities, or quality assurance considerations that traditional pharmaceutical supply chains address. While promising for policy discussions, translating these theoretical savings into practice would require substantial Medicare Part D restructuring and regulatory frameworks that currently do not exist.